HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services, with a "1+2+3+4=1" service system and direct access to silymarin extract raw materials from multiple well-known original manufacturers.
As a technology R&D-focused foreign trade enterprise, HiSiaddi has conducted multiple rounds of factory inspections of silymarin extract manufacturers and maintains objective, in-depth insights into different brands, enabling regular comparative analysis of various plant extract manufacturers for clients to identify matching products. Below is a brand selection case.
If you require further comparative analysis of brands and product models, please contact HiSiaddi customer service.
The purchaser is Naturpharma AS based in Oslo, Norway, a local mid-to-high-end medical and health enterprise specializing in prescription-grade liver-protecting soft capsules and premium oral nutrient solutions. Its products are sold nationwide at Norwegian public pharmacies, private Nordic wellness clinics, and premium organic supermarkets in Sweden. Raw material access complies with the full set of entry standards including EU EC396 standard covering 226 pesticide residue items, USP Pharmacopoeia, LFGB, and REACH. Annual silymarin extract procurement volume totals 18.8 tons, split into two raw material grades: high-purity medicinal powder for capsules and filler-free water-soluble powder for oral liquids. Mandatory indicators: silymarin ≥80%, silybin ≥30%, no added dextrin or starch, solvent residues below 3,000 ppm.
The enterprise previously sourced raw materials from Austria for years but planned to develop Chinese supply chains amid European raw material price hikes and unstable supply. During its initial visit to China, the client independently contacted five leading domestic plant extract manufacturers. Restricted by industry sales norms, each manufacturer’s sales representatives only highlighted the strengths of their own products and politely avoided or downplayed competitors without objectively explaining the process and product advantages of rival brands. The client received samples and quotations from five manufacturers with inconsistent parameters, processes, and pricing, making it impossible to distinguish which models matched its own preparation production lines. Four rounds of sample testing at Norwegian third-party laboratories uncovered issues including unstable active ingredient content, precipitation in aqueous solutions, and capsule filling clogging, stalling product selection for nearly two months. The client entrusted HiSiaddi as a neutral third party to conduct horizontal breakdown analysis of mainstream domestic brands with objective evaluation of pros and cons to screen matching product models.
HiSiaddi conducted on-site factory production line inspections, verified qualification certificates, and retrieved measured product data to objectively analyze five mainstream brands: Panjin Tianyuan Pharmaceutical, Liaoning Suji Biotechnology, Xi’an Sinuote, Shaanxi Cuida, and Shandong Kanghe Biotechnology, sorting out core strengths, weaknesses, and flagship product models for each brand without bias toward any manufacturer, and compiling complete horizontal comparison materials:
Brand strengths: Self-built 30,000 mu standardized GAP silymarin plantation base in the Greater Khingan Range, in-house GMP refining workshop, mature low-temperature staged extraction + multi-stage resin purification processes, full traceability of raw materials down to individual planting plots, industry-leading stability of silybin content, long-term supplier of multiple domestic listed pharmaceutical enterprises exporting to European and American pharmaceutical markets. Three flagship models:
1. TY-801 Medicinal Refined Powder: Silymarin 80%, silybin 30.2%, vacuum low-temperature drying with zero extra excipients, suitable for soft capsule mass production;
2. TY-S01 Water-Soluble Modified Powder: Low-temperature β-cyclodextrin inclusion without starch addition, fully soluble in cold water with zero precipitation after 90 days of storage at 4°C, dedicated to oral liquids;
3. TY-P60 Economical Ratio Powder: Silymarin 60%, low cost, only applicable to low-cost solid dietary beverages, failing to meet the client’s medicinal standards.
Brand weaknesses: Tight mass production scheduling with a 7–10 day sample preparation lead time for small batches, highest unit quotation among the five manufacturers.
Brand strengths: Relying on large-scale local planting bases in Liaoning, it holds exclusive patented nano-microcapsule coating technology delivering superior bioavailability of extracts compared with conventional products, complete EU GMP certification, fast sample delivery for small orders. Flagship models:
1. SJ-80 High-Purity Powder: Silymarin 80%, silybin 29.3%, refined via standard resin treatment;
2. SJ-W Water-Soluble Microcapsule Powder: Microcapsule-modified water-soluble raw material with excellent solubility yet containing small amounts of plant carrier excipients during production.
Weaknesses: Silybin content can hardly stabilize above the 30% threshold; the microcapsule grade contains carrier materials, violating the client’s mandatory requirement of "zero filler excipients" and rendering it incompatible with premium oral liquid formulations.
Brand strengths: Massive production capacity, abundant off-the-shelf generic products, multiple national warehousing networks for controllable short-cycle lead times, outstanding cost performance for national standard-grade raw materials. Flagship models: SN-80 Generic Silymarin Powder, SN-10 Ratio Crude Powder.
Weaknesses: Focused on mass-market dietary supplement-grade raw materials manufactured via traditional high-temperature reflux extraction leading to severe silybin losses, with measured silybin content mostly ranging from 25% to 27%. No customized low-temperature refining production lines, internal pesticide residue control only meeting national standards and unable to pass EU 226-item pesticide residue screening.
Strengths: Extensive raw material procurement channels with low quotations and fast turnover of large-batch off-the-shelf goods; flagship model CD-80 Conventional Extraction Powder.
Weaknesses: No designated GAP raw material bases with randomly mixed seeds sourced from scattered suppliers across regions leading to drastic fluctuations in active ingredient content; no supporting EU compliance testing, raw materials only suitable for low-end domestic health products and failing to meet entry thresholds for mid-to-high-end Nordic pharmaceutical enterprises.
Strengths: Complete supporting R&D laboratories enabling on-demand fine-tuning of process parameters and flexible small-batch customization; flagship models KH-80 Refined Powder, KH Water-Soluble Modified Powder.
Weaknesses: Small-scale self-owned planting bases with insufficient stability of continuous large-batch supply, prone to delivery delays due to raw material shortages during peak production seasons.
Combined with the client’s core demands of dual production lines for capsules and oral liquids, silybin ≥30%, zero filler excipients, full EU compliance, and stable large-batch supply, Sinuote and Cuida (disqualified by parameter and compliance gaps) and Suji (disqualified by excess excipients and insufficient silybin content) were eliminated. Two mid-to-high-end brands – Panjin Tianyuan Pharmaceutical and Shandong Kanghe Biotechnology – and three matching product models were finalized, split into primary mass-production stock and alternative customized backup:
1. Tianyuan TY-801 (Primary Raw Material for Soft Capsules): Stable 80% silymarin and 30.2% silybin, low-temperature refining with zero solvent residues, excellent powder fluidity compatible with the client’s automatic capsule filling line, designated as the primary mass-purchased grade for annual bulk supply;
2. Tianyuan TY-S01 (Primary Raw Material for Oral Liquids): Filler-free water-soluble modified powder without starch or maltodextrin, zero precipitation under low-temperature storage, perfectly matching oral liquid formulations and accounting for the majority of oral liquid raw material procurement;
3. Kanghe KH-80 Custom Refined Powder (Alternative Backup for New Premium Products): Indicators benchmarking TY-801 with fine-tuned processes, reserved for small-batch pilot trials of the client’s new products as an alternative supply source to mitigate single-factory supply interruption risks.
HiSiaddi coordinated unified sample delivery of the three product models from the two manufacturers, simultaneously arranging SGS laboratory testing covering 226 EU EC396 pesticide residue items and full heavy metal testing with English COA reports issued. Samples were delivered to the Norwegian pharmaceutical factory’s GMP workshop for 15 consecutive days of pilot production: TY-801 delivered capsule filling weight errors controlled within ±1.9% with zero clogging and scrapping; TY-S01 maintained crystal clarity without precipitation in oral liquids throughout low-temperature storage; KH-80 passed all indicator testing and smoothly completed new product formulation trials.
Naturpharma of Norway formally signed a long-term annual procurement framework for 18.8 tons: 17.1 tons of Tianyuan TY-801 (11.2 tons) + TY-S01 (5.9 tons), plus 1.7 tons of backup KH-80 powder from Kanghe, with monthly production scheduling split into 11 batches throughout the year and phased sea shipments from Shanghai Port to Oslo. Random Norwegian customs inspections of all consignments achieved one-time clearance every time.
Mid-to-high-end overseas pharmaceutical enterprises lack familiarity with tiered differentiation of domestic plant extract brands and segmented positioning of each manufacturer’s products. Domestic raw material manufacturers are constrained by sales-oriented operations, only promoting their own products without objective science-based introduction of competitor strengths, leaving overseas clients prone to selection errors and high sample testing loss costs during independent sourcing. As a neutral third party, HiSiaddi conducts horizontal objective evaluation of multiple brands and screens brands and product models based on end-formulation demand in reverse, mitigating production shutdown and delayed new product launch losses incurred by clients selecting mismatched raw materials while supporting high-end Chinese silymarin extract to steadily enter Nordic pharmaceutical-grade raw material supply chains. After stable cooperation, the client added organic-grade silymarin extract procurement in the following year, fully entrusting HiSiaddi with brand selection and supply chain control.
If you require further comparative analysis of brands and product models, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
